Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INBX Stock Forecast 2025-2026
$89.47
Current Price
$1.30B
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to INBX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
INBX Price Momentum
+6.4%
1 Week Change
+10.9%
1 Month Change
+469.9%
1 Year Change
+481.0%
Year-to-Date Change
-1.1%
From 52W High of $90.50
+728.0%
From 52W Low of $10.81
📊 TOP ANALYST CALLS
Did INBX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inhibrx is one of their latest high-conviction picks.
Latest INBX Stock Price Targets & Analyst Predictions
INBX has shown a year-to-date change of 481.0% and a 1-year change of 469.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for INBX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INBX Analyst Ratings
0
Buy
1
Hold
0
Sell
INBX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $89.47
Latest INBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 22, 2025 | JMP Securities | Reni J. Benjamin | Market Perform | Reiterates | $N/A |
| May 15, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $N/A |
| Mar 18, 2025 | Citizens Capital Markets | Reni Benjamin | Market Perform | Reiterates | $N/A |
| Jan 22, 2025 | JMP Securities | Reni Benjamin | Market Perform | Reiterates | $N/A |
| Jul 23, 2024 | JMP Securities | Reni Benjamin | Market Perform | Initiates | $N/A |
| Jan 23, 2024 | JMP Securities | Reni Benjamin | Market Perform | Downgrade | $N/A |
| Nov 20, 2023 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $27.00 |
| Aug 23, 2023 | JMP Securities | Reni Benjamin | Outperform | Maintains | $27.00 |
| May 10, 2023 | JMP Securities | Benjamin Chaiken | Market Outperform | Reiterates | $35.00 |
| Mar 8, 2023 | JMP Securities | Benjamin Chaiken | Market Outperform | Maintains | $35.00 |
| Mar 7, 2023 | Credit Suisse | Judah Frommer | Outperform | Reiterates | $46.00 |
| Nov 8, 2022 | Credit Suisse | Judah Frommer | Outperform | Maintains | $46.00 |
| Oct 5, 2022 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $60.00 |
| Aug 25, 2022 | SMBC Nikko | Outperform | Initiates | $N/A | |
| Aug 9, 2022 | Credit Suisse | Judah Frommer | Outperform | Maintains | $48.00 |
| Mar 16, 2022 | SMBC Nikko | Outperform | Initiates | $N/A | |
| Mar 2, 2022 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $40.00 |
| Nov 10, 2021 | Credit Suisse | Judah Frommer | Outperform | Maintains | $53.00 |
| Nov 2, 2021 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $53.00 |
| Sep 21, 2021 | JMP Securities | Market Outperform | Initiates | $N/A |
Inhibrx Biosciences, Inc. (INBX) Competitors
The following stocks are similar to Inhibrx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inhibrx Biosciences, Inc. (INBX) Financial Data
Inhibrx Biosciences, Inc. has a market capitalization of $1.30B with a P/E ratio of 0.2x. The company generates $1.40M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -13,937.9% and return on equity of -144.1%.
Valuation Metrics
Market Cap
$1.30B
Enterprise Value
$1.23B
P/E Ratio
0.2x
PEG Ratio
0.0x
Price/Sales
894.6x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-13,937.9%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.8%
Current Ratio
4.5x
Debt/Equity
290.3x
ROE
-144.1%
ROA
-61.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Inhibrx Biosciences, Inc. (INBX) Business Model
About Inhibrx Biosciences, Inc.
What They Do
Develops monoclonal antibodies for life-threatening diseases.
Business Model
Inhibrx Inc. operates by innovating targeted therapies using its proprietary single-domain antibody technology platform. The company generates revenue through the development and commercialization of these highly differentiated biological therapies, focusing on areas with significant unmet medical needs such as oncology, rare diseases, and autoimmune conditions.
Additional Information
Positioned in the fast-growing biotechnology sector, Inhibrx is appealing to investors interested in high-growth opportunities within healthcare innovations. The company's focus on precision medicine aims to improve patient outcomes and contribute to advancements in medical research.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
156
CEO
Mr. Mark Paul Lappe
Country
United States
IPO Year
2020
Website
inhibrx.comInhibrx Biosciences, Inc. (INBX) Latest News & Analysis
Latest News
Quick Summary
Inhibrx Biosciences reported Q3 2025 financial results following the sale of INBRX-101 to Sanofi S.A. The transaction marks a significant development for the company.
Why It Matters
Inhibrx's Q3 2025 financial results and the sale of INBRX-101 to Sanofi could impact stock value, reflecting company performance and strategic partnerships.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Inhibrx Biosciences (Nasdaq: INBX) will present clinical data on its DR5 Agonist at multiple conferences in November 2025, highlighting its potential in treating various cancers.
Why It Matters
Inhibrx's upcoming presentations on clinical data for its DR5 agonist could signal advancements in cancer treatment, potentially impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Inhibrx Biosciences reported positive phase 2 results for ozekibart in chondrosarcoma, doubling progression-free survival. A BLA filing is planned by Q2 2026, with additional data for INBRX-106 expected in Q4 2025.
Why It Matters
Strong phase 2 results for ozekibart enhance Inhibrx’s pipeline and potential market position. Upcoming BLA filing and additional data catalysts may drive stock growth and investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Inhibrx Biosciences reported positive mid-stage trial results for its experimental drug targeting rare bone cancer, leading to a 70% surge in shares during extended trading.
Why It Matters
The positive trial results for Inhibrx's drug indicate potential market value growth, attracting investor interest and leading to a significant spike in stock prices.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Inhibrx's ozekibart shows significant improvement in progression-free survival in chondrosarcoma patients. A BLA filing is planned for Q2 2026. Positive interim data in colorectal cancer and Ewing sarcoma reported.
Why It Matters
Ozekibart's success in improving progression-free survival in chondrosarcoma could lead to regulatory approval, boosting Inhibrx's stock and market position in oncology therapeutics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Inhibrx Biosciences will host a live webcast on October 23, 2025, at 1:30 p.m. PT, focusing on its developments in oncology and rare disease therapeutics.
Why It Matters
Inhibrx's webcast may reveal key updates on their drug development progress, impacting stock performance and investor sentiment in the biopharmaceutical sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INBX Stock
What is Inhibrx Biosciences, Inc.'s (INBX) stock forecast for 2026?
Analyst forecasts for Inhibrx Biosciences, Inc. (INBX) are not currently available. The stock is trading at $89.47.
Is INBX stock a good investment in 2026?
According to current analyst ratings, INBX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $89.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INBX stock?
Price predictions from Wall Street analysts for INBX are not currently available. The stock is trading at $89.47.
What is Inhibrx Biosciences, Inc.'s business model?
Inhibrx Inc. operates by innovating targeted therapies using its proprietary single-domain antibody technology platform. The company generates revenue through the development and commercialization of these highly differentiated biological therapies, focusing on areas with significant unmet medical needs such as oncology, rare diseases, and autoimmune conditions.
What is the highest forecasted price for INBX Inhibrx Biosciences, Inc.?
Price targets from Wall Street analysts for INBX are not currently available. The stock is trading at $89.47.
What is the lowest forecasted price for INBX Inhibrx Biosciences, Inc.?
Price targets from Wall Street analysts for INBX are not currently available. The stock is trading at $89.47.
What is the overall INBX consensus from analysts for Inhibrx Biosciences, Inc.?
The overall analyst consensus for INBX is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are INBX stock price projections?
Stock price projections, including those for Inhibrx Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 8:52 AM UTC